WASHINGTON – Biopharma's part of the tab to reduce the nation's deficit includes a shorter exclusivity for biologics, steeper Medicare rebates and stiffer penalties under President Barack Obama's proposal to trim $3.5 trillion from the debt over the next 10 years.